Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing Capricor’s reported financial details
- Investor focus: cash position, operating expenses, pipeline progress, and funding needs in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Deramiocel BLA remains under FDA review, preserving approval potential despite a non-binding 3–9 advisory committee vote against cardiomyopathy efficacy
- HOPE-3 primary endpoint achieved statistical significance in upper-limb function at p=0.029, supporting the company’s regulatory case
- Cash, equivalents and marketable securities $237.9M versus $318.1M at December 31, 2025, with funding expected for at least twelve months
- Second-quarter operating expenses rose to $42.9M from $27.7M, driving net loss of $40.7M versus $25.9M
- FDA BIMO inspection cited one Form 483 observation, adding execution risk while the company awaits agency feedback
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.